Table 4. Clinical diagnosis and seroprevalence of anti-Toxocara IgG antibodies in psychiatric patients in Shandong Province, eastern China.

Clinical Diagnosis	ICD-10 diagnosis	Patients with anti-Toxocara IgG antibodies
		No. tested	No.	% (95%CI)	P value*
Epilepsy	G40	49	17	34.69 (21.37–48.02)	<0.0001
Affective disorder	F30, F39	13	1	7.69 (0.00–22.18)	0.5664
Somatoform disorder	F45	36	5	13.89 (2.59–25.19)	0.8853
Schizophrenia	F20	34	5	14.71 (2.80–26.61)	0.7797
Mental and behavioural disorders due to use of alcohol	F10, F18	53	8	15.09 (5.46–24.73)	0.6680
Mental and behavioural disorders due to use of drug	F13, F15, F19	26	2	7.69 (0.00–17.94)	0.4188
Obsessive-compulsive disorder	F42	29	5	17.24 (3.49–30.99)	0.5103
Mild depression	F32.051	23	3	13.03 (0.00–26.81)	0.9973
Moderate depression	F32.151	52	6	11.54 (2.86–20.22)	0.7475
Major depressive disorder	F32.251	39	3	7.69 (0.00–16.06)	0.3235
Mental retardation	F71–37, F78	40	7	17.50 (5.73–29.28)	0.4139
Alzheimer's disease	G30	33	7	21.21 (7.26–35.16)	0.1725
Dementia in Alzheimer's disease with early onset	F00.0	18	4	22.22 (3.02–41.43)	0.2539
Total		445	73	16.40 (12.96–19.85)	0.0752

*As compared with 13.07% seroprevalence of anti-Toxocara IgG antibodies in clinically healthy individuals (187/1431).